Scinai Immunotherapeutics Ltd.
SCNI
$0.51
-$0.03-5.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.31M | 1.25M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.31M | 1.25M | -- | -- | -- |
| Cost of Revenue | 3.96M | 3.38M | -- | -- | -- |
| Gross Profit | -2.65M | -2.13M | -- | -- | -- |
| SG&A Expenses | 2.52M | 2.65M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.85M | 9.16M | -- | -- | -- |
| Operating Income | -7.54M | -7.92M | -- | -- | -- |
| Income Before Tax | -8.31M | -8.45M | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.31 | -8.45 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.31M | -8.45M | -- | -- | -- |
| EBIT | -7.54M | -7.92M | -- | -- | -- |
| EBITDA | -6.12M | -6.35M | -- | -- | -- |
| EPS Basic | -15.81K | -35.85K | -- | -- | -- |
| Normalized Basic EPS | -2.47 | -10.64 | -- | -- | -- |
| EPS Diluted | -15.81K | -35.85K | -- | -- | -- |
| Normalized Diluted EPS | -2.47 | -10.64 | -- | -- | -- |
| Average Basic Shares Outstanding | 9.34M | 7.50M | -- | -- | -- |
| Average Diluted Shares Outstanding | 2.00K | 1.60K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |